Search | IOVS | ARVO Journals

Showing 1 – 20 of 72

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Outcomes of Exudative Retinal Detachments in Choroidal Melanoma

Megan Steinkerchner; Anne Marie Lane; Evangelos S Gragoudas; Ivana K Kim; Frances Wu

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2249.

ARVO Annual Meeting Abstract June 2023

Impact of Gene Expression Profiling on Diagnosis and Survival after Metastasis in Patients with Uveal Melanoma

Ashley Go; Disorn Suwajanakorn; Anne Marie Lane; Caleb Hartley; Monica Oxenreiter; Mary E Aronow; Evangelos S Gragoudas; Ivana K Kim

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):880.

ARVO Annual Meeting Abstract June 2023

Confirmatory cytopathology and potential impact on the predictive value of GEP

Caleb Hartley; Ronan McCarthy; Anne Marie Lane; Ashley Go; Disorn Suwajanakorn; Frances Wu; Mary E Aronow; Evangelos S Gragoudas; Ivana K Kim

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):3620.

Anatomy and Pathology/Oncology April 2021

Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin

PDF

Niels J. Brouwer; Eleni K. Konstantinou; Evangelos S. Gragoudas; Marina Marinkovic; Gregorius P. M. Luyten; Ivana K. Kim; Martine J. Jager; Demetrios G. Vavvas
TAGS: bap1 gene, cell growth, cell lines, genes, malignant melanoma of conjunctiva, mutation, neoplasms, uvea, verteporfin, proteins
Invest. Ophthalmol. Vis. Sci.. 2021; 62(4):3. https://doi.org/10.1167/iovs.62.4.3

Includes: Supplemental Content

ARVO Imaging in the Eye Conference Abstract August 2019

Analysis of Vascular Changes after Proton Irradiation using OCT-A in Patients with Uveal Melanoma

Gary Lamoureux; Jay Wang; Anne Marie Lane; Monica Oxenreiter; Alexei V Trofimov; John B Miller; Helen A Shih; Mary Beth Aronow; Ivana K Kim; Evangelos S Gragoudas

Invest. Ophthalmol. Vis. Sci.. 2019; 60(11):PB059.

ARVO Annual Meeting Abstract July 2019

Efficacy of immune checkpoint inhibitors for treating uveal melanoma metastases

Monica Oxenreiter; Anne Marie Lane; Justine V Cohen; Ryan J Sullivan; Ivana K Kim; Evangelos S Gragoudas

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):742.

ARVO Annual Meeting Abstract July 2019

Anti-VEGF Non-Responders are often short-term responders

Saghar Bagheri; Georgios Bontzos; Larisa Ioannidi; Stamatina Kabanarou; Ivana K Kim; Evangelos S Gragoudas; Joan W Miller; IOANNIS DATSERIS; Miltiadis K. Tsilimbaris; Demetrios Vavvas

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):77.

ARVO Annual Meeting Abstract July 2018

Macular perfusion status in eyes with choroidal melanoma treated with prophylactic ranibizumab after proton beam irradiation

Mary E Aronow; Jay Wang; Anne Marie Lane; Monica Oxenreiter; Evangelos S Gragoudas; Ivana Kim

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4301.

ARVO Annual Meeting Abstract July 2018

A comparison of treatment outcomes in patients receiving standard dose vs. reduced dose proton radiation for uveal melanoma

Monica Oxenreiter; Anne Marie Lane; Ivana Kim; Evangelos S Gragoudas

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3626.

Retina March 2018

Genetic Risk Factors for Radiation Vasculopathy

PDF

Thanos D. Papakostas; Margaux A. Morrison; Anne Marie Lane; Caroline Awh; Margaret M. DeAngelis; Evangelos S. Gragoudas; Ivana K. Kim
TAGS: genetic risk, radiation, single nucleotide polymorphism, vascular diseases, visual impairment, visual acuity
Invest. Ophthalmol. Vis. Sci.. 2018; 59(3):1547-1553. https://doi.org/10.1167/iovs.17-22791

ARVO Annual Meeting Abstract June 2017

Evaluation of Choroidal Nevi with Swept-Source Optical Coherence Tomography

Cindy Ung; Ines Lains; Russell L Woods; Anne Marie Lane; Deeba Husain; Joan W Miller; Evangelos S Gragoudas; Ivana K Kim; John B Miller

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1882.

ARVO Annual Meeting Abstract June 2017

Verteporfin-induced formation of protein oligomers is mediated by light and leads to cell toxicity.

Eleni Konstantinou; Shoji Notomi; Katarzyna Brodowska; Ahmad Moujahed; Fotini Nicolaou; Pavlina Tsoka; Evangelos S Gragoudas; Joan W Miller; Lucy Young; Demetrios G. Vavvas

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2966.

ARVO Annual Meeting Abstract June 2017

MANAGEMENT OF SUSPICIOUS MELANOCYTIC LESIONS OF THE IRIS

Monica Oxenreiter; Anne Marie Lane; Ivana K Kim; Evangelos S Gragoudas

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4419.

Lecture December 2016

Introducing Joan W. Miller, the 2015 Recipient of the Weisenfeld Award

PDF

Evangelos S. Gragoudas
TAGS: awards and prizes
Invest. Ophthalmol. Vis. Sci.. 2016; 57(15):6910. https://doi.org/10.1167/iovs.15-18205

ARVO Annual Meeting Abstract September 2016

Genetic Risk Factors for Radiation Vasculopathy

Thanos D Papakostas; Anne Marie Lane; Caroline Awh; Margaux Morrison; Margaret M DeAngelis; Evangelos S Gragoudas; Ivana K Kim

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):4096.

ARVO Annual Meeting Abstract September 2016

Verteporfin inhibits growth of human ocular glioma in vitro without light activation

Ahmad Al Moujahed; Katarzyna Brodowska; Tomasz Stryjewski; Joanna Cichy; Evangelos S Gragoudas; Demetrios G. Vavvas

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):4109.

ARVO Annual Meeting Abstract June 2015

Deferoxamine inhibits the growth of uveal melanoma cells in vitro

Thanos D Papakostas; Fotini Nicolaou; Ahmad Al-Moujahed; John B Miller; Haijiang Lin; Evangelos S Gragoudas; Demetrios Vavvas

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5320.

ARVO Annual Meeting Abstract April 2014

Verteporfin Without Photodynamic Therapy: Effect of the Photosensitizer on Ocular Cell Lines

Peggy Bouzika; Haijiang Lin; Yueran Yan; Yijun Hu; Alp Atik; Joan W Miller; Evangelos S Gragoudas; Demetrios G Vavvas

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1966.

ARVO Annual Meeting Abstract April 2014

Clinical characteristics of uveal melanoma in patients with germline BAP1 mutations

Mrinali Patel; Margaret M DeAngelis; Anne Marie Lane; Katie Mayne; Evangelos S Gragoudas; Ivana K Kim

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):6443.

ARVO Annual Meeting Abstract April 2014

Verteporfin (VP) inhibits human retinoblastoma cell growth in vitro without light activation.

Katarzyna Brodowska; Ahmad Al Moujahed; Anna Marmalidou; Melissa Meyer zu Horste; Joanna Cichy; Joan W Miller; Evangelos S Gragoudas; Demetrios G Vavvas

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):849.

1 2 3 4

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Outcomes of Exudative Retinal Detachments in Choroidal Melanoma

Impact of Gene Expression Profiling on Diagnosis and Survival after Metastasis in Patients with Uveal Melanoma

Confirmatory cytopathology and potential impact on the predictive value of GEP

Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin

Analysis of Vascular Changes after Proton Irradiation using OCT-A in Patients with Uveal Melanoma

Efficacy of immune checkpoint inhibitors for treating uveal melanoma metastases

Anti-VEGF Non-Responders are often short-term responders

Macular perfusion status in eyes with choroidal melanoma treated with prophylactic ranibizumab after proton beam irradiation

A comparison of treatment outcomes in patients receiving standard dose vs. reduced dose proton radiation for uveal melanoma

Genetic Risk Factors for Radiation Vasculopathy

Evaluation of Choroidal Nevi with Swept-Source Optical Coherence Tomography

Verteporfin-induced formation of protein oligomers is mediated by light and leads to cell toxicity.

MANAGEMENT OF SUSPICIOUS MELANOCYTIC LESIONS OF THE IRIS

Introducing Joan W. Miller, the 2015 Recipient of the Weisenfeld Award

Genetic Risk Factors for Radiation Vasculopathy

Verteporfin inhibits growth of human ocular glioma in vitro without light activation

Deferoxamine inhibits the growth of uveal melanoma cells in vitro

Verteporfin Without Photodynamic Therapy: Effect of the Photosensitizer on Ocular Cell Lines

Clinical characteristics of uveal melanoma in patients with germline BAP1 mutations

Verteporfin (VP) inhibits human retinoblastoma cell growth in vitro without light activation.

To View More...

You must be signed into an individual account to use this feature.